Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.Jean‐Charles Soria, Michael Millward, T.R. Jeffry Evans et al.|Journal of Clinical Oncology|2012Cited by 14
610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent MesotheliomaJean‐Charles Soria, M.J. Millward, Ruth Plummer et al.|European Journal of Cancer|2012Cited by 8
613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid TumorsHui Gan, M.J. Millward, Noelia Nebot et al.|European Journal of Cancer|2012Cited by 3